Research programme: anti-RANKL therapeutics - Pharmexa
Alternative Names: AutoVac RANKL vaccine - Pharmexa; ME 107; Osteoporosis vaccine - Pharmexa; PX 107; PX 107 RANKL AutoVac; RANKL AutoVac; RANKL vaccine - PharmexaLatest Information Update: 25 Jun 2009
At a glance
- Originator Pharmexa
- Class Vaccines
- Mechanism of Action Bone resorption factor inhibitors; Immunostimulants; Osteoclast inhibitors; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone disorders; Osteoporosis
Most Recent Events
- 22 Jun 2009 Affitech AS has merged with Pharmexa to form Affitech A/S
- 27 Feb 2008 Suspended - Preclinical for Bone disorders in Denmark (Parenteral)
- 27 Feb 2008 Suspended - Preclinical for Osteoporosis in Denmark (Parenteral)